Mangoceuticals, Inc. Net Fee Amt
Mangoceuticals, Inc. (MGRX) had Net Fee Amt of $80.1 as of 2026-07-10, per its S-8 filed 2026-07-10.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-10
- 2026-07-10: Net Fee Amt $80.10.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-10 | $80.10 S-8 · filed 2026-07-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |